CMPS COMPASS Pathways Plc - American Depository Shares

COMPASS Pathways (CMPS) is back in focus after recent share price swings, with the mental health biotech drawing attention as investors reassess its psilocybin-based COMP360 pipeline and current valuation. Recent trading tells a mixed story for COMPASS Pathways. The share price fell around 4% over the last day and is down about 10% over the past week, yet the year to date share price return is close to 90% and the 1 year total shareholder return is roughly 116%. That combination suggests...

Compass Pathways (NASDAQ:CMPS) executives said the company remains on track to complete its rolling New Drug Application submission for COMP360 in the fourth quarter, while preparing commercial infrastructure for a potential U.S. launch following FDA approval and federal rescheduling. Speaking at T

Helus Pharma, formerly known as Cybin (NASDAQ:HELP), outlined its late-stage development plans for HLP-003 in adjunctive major depressive disorder (MDD) and discussed its broader pipeline of serotonergic agonists during TD Cowen’s Novel Mechanisms in Neuropsychiatry virtual summit. Michael Halstead

Compass Pathways (NASDAQ:CMPS) said it remains on track to complete its rolling New Drug Application submission for COMP360 in the fourth quarter of 2026, following positive Phase III studies of its synthetic psilocybin treatment in treatment-resistant depression, or TRD. During H.C. Wainwright’s G

Compass Pathways (NASDAQ:CMPS) expects to complete its new drug application submission for COMP360, its investigational psilocybin treatment for treatment-resistant depression, in the fourth quarter, with a potential U.S. launch in the first half of 2027, executives said at the Morgan Stanley Global

Cybin (NASDAQ:HELP), doing business as Helus Pharma, held its Annual General and Special Meeting of Shareholders, where shareholders were asked to consider resolutions related to the company’s auditor, board size, corporate name and director elections. Eric So, the company’s co-founder and executiv

Compass Pathways (NASDAQ:CMPS) said it expects to complete its rolling New Drug Application submission for its synthetic psilocybin treatment, COMP360, in the fourth quarter and continues to target a potential commercial launch for treatment-resistant depression in the first half of 2027. Speaking

Cybin (NASDAQ:HELP) executives outlined plans for its late-stage depression program, including an expected fourth-quarter Phase 3 data readout for HLP003, during H.C. Wainwright’s 28th Annual Global Investment Conference. The company, referred to in the presentation as Helus Pharma, is developing se

Helus Pharma Chief Executive Officer Michael Halstead said the company expects a pivotal Phase III readout for its HLP003 program in adjunctive major depressive disorder in the fourth quarter, describing the data as a key near-term catalyst for the company’s mental health treatment pipeline. Speaki

COMPASS Pathways has been back in the spotlight, with fresh clinical data on its COMP360 psilocybin therapy and a sharply higher share price putting a simple question on the table. After such a move, investors are asking whether the current market value of Compass Pathways is still anchored in the strength of its book value. Over the past year the stock has delivered a return of 170.8%, which puts a lot of weight on whether the underlying balance sheet can support that kind of...

Compass Pathways (NASDAQ:CMPS) climbed 4% on Wednesday after new 52-week data from the company's Phase III study of COMP360, its investigational oral psilocybin treatment for treatment-resistant depression (TRD). The data, from the open-label Part C portion of Study '005, showed sustained...

Compass said patients who received an additional 25 mg dose of COMP360 saw their depression scores improve by an average of 13 points after 52 weeks.

Compass Pathways plc (NASDAQ:CMPS) reported 52-week topline results from Part C of its Phase 3 COMP005 trial evaluating COMP360, its synthetic psilocybin formulation, in treatment-resistant depression. The open-label portion of the study covered Week 26 through Week 52 and included approximately 70% of the original 258 U.

Oil was once again at the center of investors’ attention, with Brent crude futures climbing above $100 per barrel for the first time since July

Compass has said a rolling FDA application is already underway for its COMP360, with the package due to be completed in the fourth quarter of 2026 and a possible U.S. launch in the first half of 2027.

The most closely watched next step for Compass is the completion of its application to the U.S. Food and Drug Administration for COMP360, its synthetic psilocybin treatment aimed at people with depression that has not responded to other options.

Helus Pharma CEO Michael Halstead said the company is preparing for a potentially pivotal period as it expects top-line results in the fourth quarter from its first Phase III trial of HLP003 as an adjunctive treatment for major depressive disorder. Speaking at a Canaccord Genuity event, Halstead, w

COMP360 shows 39% response rate; commercial launch targeted for H1 2027.

Compass Pathways (NASDAQ:CMPS) said it remains on track to complete a new drug application for COMP360, its investigational psilocybin treatment for treatment-resistant depression, in the fourth quarter of this year, with a potential U.S. launch expected in the first half of 2027. During Canaccord

Key Takeaways; Cannabis Sector Canopy Growth Posted 13% Revenue Growth as Losses Narrowed Sharply in Q1 FY2027 Aurora Cannabis Narrowed Q1 Loss as International Medical Cannabis Growth Gained Ground Cronos Group Reported Record Q2 Revenue as Profitability and EBITDA Surged Key Takeaways; Psychedelic Sector Compass Pathways is Building Momentum Toward Potential COMP360 Launch as Veterans […]

COMPASS Pathways (NasdaqGS:CMPS) just announced a collaboration with the U.S. Department of Veterans Affairs on the PIVOT trial, a multi site study of COMP360 psilocybin in veterans with treatment resistant depression. See our latest analysis for COMPASS Pathways. The PIVOT trial news lands after an intense period for COMPASS Pathways, with a sharply wider Q2 2026 loss and a recent shelf registration filing that may shape future funding options. Even so, the stock’s 90 day share price return...

Compass Pathways PLC (CMPS) reports $433 million in cash and advances rolling NDA submission for COMP360 in treatment-resistant depression, targeting a first-half 2027 launch.

Compass Pathways (NASDAQ:CMPS) said it remains on track to complete its new drug application, or NDA, filing for COMP360 in treatment-resistant depression in the fourth quarter of 2026, following positive Phase III results and six-month durability data from two trials. Chief Executive Officer Kabir

Cathie Wood is loading up on shares of a biotech that could be one of the first entrants to the psychedelics market.

Wells Fargo began coverage on five biotech stocks on Monday, with only Compass Pathways receiving an ‘Equal-Weight’ rating while the rest received ‘Overweight’ ratings.

Watch Fireside Chat Below, or Click HERE: IPO Edge hosted a fireside chat with Jupiter Neurosciences, Inc. (Nasdaq: JUNS) Chairman, Chief Executive Officer and Co-founder Christer Rosén and Alison Silva, […]